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We have been able to reduce substantially patient pool heterogeneity by identifying
phenotypic markers that allow the researcher to stratify chronic fatigue syndrome (CFS)
patients into subgroups. To date, we have shown that stratifying based on the presence or
absence of comorbid psychiatric diagnosis leads to a group with evidence of neurological
dysfunction across a number of spheres. We have also found that stratifying based on
the presence or absence of comorbid fibromyalgia leads to information that would not
have been found on analyzing the entire, unstratified patient group. Objective evidence
of orthostatic intolerance (OI) may be another important variable for stratification and
may define a group with episodic cerebral hypoxia leading to symptoms. We hope that
this review will encourage other researchers to collect data on discrete phenotypes in
CFS to allow this work to continue more broadly. Finding subgroups of CFS suggests
different underlying pathophysiological processes responsible for the symptoms seen.
Understanding those processes is the first step toward developing discrete treatments
for each.
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Chronic fatigue syndrome (CFS) is a medically unexplained ill-
ness characterized by new onset of fatigue, severe enough to
produce a substantial decrease in activity, and accompanied
by infectious, rheumatological, and neuropsychiatric symptoms
(Fukuda et al., 1994). One of the most common and disabling
symptoms is the subjective complaint of “brain fog” or inability
to concentrate and do multiple tasks at the same time. Our earli-
est study provided objective evidence of a problem with attention
and concentration (DeLuca et al., 1993).
Because CFS is defined using a clinical case definition, patients
with this diagnosis must constitute a heterogeneous group, prob-
ably with multiple causative agents—much as was the case of
the eighteenth century diagnosis of dropsy. The condition of
dropsy evolved to a host of more specific diagnoses includ-
ing congestive heart failure and other organ failures when the
pathological causes of the specific organ dysfunction leading to
dropsy were discovered. Our approach has been to try to strat-
ify along certain phenotypic criteria to try to develop more
homogeneous subgroups. In contrast, some researchers have been
impressed by the large amount of comorbidity occurring among
several of these syndromes—namely, CFS and fibromyalgia (FM).
Confirming this with data from our Center, we found ∼37% of
patients with CFS also fulfilled case criteria for FM (Ciccone and
Natelson, 2003), and one study of patients with FM reported that
about 20% also fulfilled criteria for CFS (Buchwald and Garrity,
1994). Regarding this overlap between syndromes, Wessely et al.
(1999), for example, have suggested that the “similarities between
them outweigh the differences” and Barsky and Borus (1999),
noting similarities between CFS and FM, suggested an explana-
tory model based on the concept of symptom amplification—that
is, a common psychological tendency to somatize or miscon-
strue the significance of normal physical sensation. Moving from
the question as to whether CFS and FM are the same or differ-
ent illnesses is the conclusion that many patients with CFS have
their illness based on somatization. We did explore this hypoth-
esis early on and learned that the probability of any one patient
receiving the diagnosis of Somatization Disorder depended on
whether or not his/her symptoms were coded as psychiatric or
physical. If the coder decided the infectious, rheumatological,
and neuropsychiatric symptoms of CFS were psychiatric, then
nearly every patient would be classified as having Somatization
Disorder, but if the symptoms were coded as physical, then
nearly none would be so classified. Based on this assessment,
we eschewed the idea of “lumping” patients into one explana-
tory rubric and have continued our efforts to “split” patients into
discrete subgroups.
Over the years, we have used two major strategies for stratify-
ing patients. The first used the presence or absence of comorbid
psychiatric diagnosis—usually major depressive disorder. Our
first target was the neuropsychological dysfunction we had orig-
inally reported (DeLuca et al., 1993). In a follow up study, we
stratified our patients into those with or without comorbid Axis
I diagnoses: we found that the group with no comorbid psychi-
atric diagnoses was the group with the worst neuropsychological
test results (DeLuca et al., 1997). After doing an initial study
which showed increased numbers of anatomic abnormalities on
www.frontiersin.org May 2013 | Volume 4 | Article 109 | 1
Natelson Genesis of symptoms in CFS
brain magnetic resonance imaging (Natelson et al., 1993), we fol-
lowed that study up after stratifying our patients into PSYCH or
NO-PSYCH groups. Again, we found that the patients without
psychiatric comorbidity were the ones with the highest number
of abnormalities—usually small, circumscribed areas of T2 signal
in frontal lobes (Lange et al., 1999). To start determining whether
these were insignificant epiphenomena or perhaps functioned to
affect physical function, we asked if physical function as assessed
by the SF-36 correlated with MRI findings and in fact found that
those with the lesions had worse physical function than those
with normal brain MRIs (Cook et al., 2001). Our findings of
increased numbers of abnormalities in the NO-PSYCH patients
are of interest when compared to a subset analysis of an ear-
lier study (Greco et al., 1997): while no significant difference in
rate of abnormalities was found between a group of unstratifed
patients and controls, they did report a difference significant at
the 0.06 level between a subgroup of patients without depression
compared to healthy controls; thus our data do replicate this find-
ing. The sum of these data suggests that some CFS patients may
have a brain marker of their disease in the form of small nonspe-
cific MRI white matter abnormalities, occurring predominantly
in the frontal lobes. These studies led to our current working
hypothesis—that a subgroup of patients with CFS has an under-
lying neurological disease which leads to the symptoms of fatigue
and cognitive dysfunction.
Using the same stratification strategy, we moved on to other
studies. First, we collected spinal fluid from 45 CFS patients and
13 healthy controls. As expected, the healthy controls had white
blood counts per high power field and protein concentrations
that were all below the high value for laboratory normals. In con-
trast, we found that nearly 30% of the patients had elevations
in one or both of these variables. While there was no difference
in lifetime rates of Axis I pathology, the group with the abnor-
mal spinal fluids had significantly fewer cases with a diagnosis
of current depression than the group with the normal spinal
fluids (Natelson et al., 2005). Our next study looked at cere-
bral blood flow in CFS (Yoshiuchi et al., 2006). We found that
CFS patients as a group had significant reductions in cerebral
blood flow across a number of brain in regions. However, those
patients with no comorbid psychiatric diagnosis had more areas
of reduced blood flow compared to controls than patients who
did have comorbid psychiatric diagnoses. Finally, we re-evaluated
data on ventricular lactate which had shown increases for CFS
relative to controls (Mathew et al., 2009). Nine of the 16 CFS
patients fell into a “high” group (i.e., displaying higher ventric-
ular lactate levels that were one SD above the CFS group mean)
which was higher than every healthy volunteer and was responsi-
ble for the overall group effect. In exploratory post-hoc analyses,
these 9 CFS patients were compared with the remaining 6 CFS
patients with normal lactate levels (“normal”), which revealed
that the only differences between the two CFS subgroups was
greater overall functional disability on the SF-36 (P = 0.039), and
a trend toward greater lifetime Axis I mood disorder comorbid-
ity (4 of 7 vs. 1 of 9, Fisher Exact probability test, P = 0.07) in
the CFS group with “low” lactate levels compared to CFS patients
with higher ventricular lactate (Mathew et al., unpublished data).
Although preliminary, these data suggest that “no-psych” patients
may have an underlying encephalopathy producing the symptoms
of CFS.
The other way we have stratified our CFS patient sample is
on the presence or absence of fibromyalgia—characterized by the
patient reporting widespread pain and having tenderness in at
least 11 of 18 tender points subjected to palpation (Wolfe et al.,
1990).When comparing CFS patients with andwithout comorbid
fibromyalgia, we found that only patients in the CFS only group
and not those with both CFS plus fibromyalgia had abnormal
neuropsychological test results (Cook et al., 2005). A recent paper
from another group corroborated our finding of normal cogni-
tive function in fibromyalgia (Mohs et al., 2012). Unfortunately,
we do not have data as to psychiatric status for these subjects;
however other studies have revealed that patients with CFS only
have approximately half the psychiatric comorbidity than those
with comorbid FM (Ciccone and Natelson, 2003); these data
support our working hypothesis that the group of CFS patients
with no co-existing psychiatric problems has an underlying brain
disease.
These results support our hypothesis that stratifying CFS
patients into subgroups can lead to improved understanding of
the cognitive complaints of all CFS patients. We have two major
hypotheses for how the changes in blood flow affect neural func-
tioning adversely, leading to increased ventricular lactate and/or
small lesions in frontal white matter, and then to symptoms.
The first of these, spearheaded by my colleague Dr. Dikoma
Shungu of Weil-Cornell, is an outgrowth of Martin Pall’s hypoth-
esis (Pall, 2000) that some immunological or infectious trigger
activates one or more pro-inflammatory cytokines which induce
a synthesis chain leading to the production of peroxynitrite, a
potent pro-apoptotic, and pro-inflammatory reactive oxygen or
nitrogen species (Hoffman et al., 1997; Basu, 2008). This pro-
cess is inhibited by adequate antioxidant capacity/reserves, of
which glutathione (GSH) is the most abundant and important
component. In the face of inadequate levels of antioxidants, per-
oxynitrite will react with arachidonic acid in cell membrane
phospholipids, to form isoprostanes, compromising membrane
and cell function. A final metabolic step frees the isoprostanes
from the cell membrane phospholipids, allowing them to move
into body fluids, where they can be measured to provide an
objective and reliable measure for the presence of oxidative
stress.
This model is pertinent to CFS for the following reasons:
first, two studies have reported that isoprostanes are elevated
in CFS (Kennedy et al., 2005; Robinson et al., 2009). And sec-
ond, we have found that cortical GSH is reduced by 36% in
CFS (Shungu et al., 2012). These data lead to the inference
that brain oxidative stress molecules are increased in CFS; these
molecules have potent vasoconstrictor effects on cerebral arteri-
oles (Hoffman et al., 1997) and thus could explain the decreases
in regional cerebral blood flow that we have now found in a
number of studies (Yoshiuchi et al., 2006; Biswal et al., 2011;
Shungu et al., 2012). Finally the impaired cellular metabolism
produced by these molecules could, via co-occurring increases
in anaerobic glycolytic activity, lead to the increased ventricular
CSF lactate in CFS shown to occur by Shungu and colleagues
in three separate studies (Mathew et al., 2009; Murrough et al.,
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2010; Shungu et al., 2012). One possibility that our studies
have ruled out is mitochondrial dysfunction from the accumu-
lation of free radicals: we found brain ATP and associated high
energy phosphates to be normal in CFS (Shungu et al., 2012).
Thus, we are focusing on the oxidative stress hypothesis in this
model of CFS.
The second explanatory hypothesis is directed to the ∼25% of
CFS patients with physiological evidence of orthostatic intoler-
ance (OI). Early work by David Streeten (Streeten and Anderson,
1992) tied chronic symptoms including fatigue to a form of
OI characterized by delayed hypotension induced by orthostatic
stress. Subsequent work made the link with CFS directly. The
researchers did tilt testing with pharmacological potentiation in
young adults with CFS and reported that most patients developed
delayed hypotension accompanied by increased fatigue com-
pared to healthy controls (Bou-Holaigah et al., 1995). While
several groups have replicated this finding in older patient pop-
ulations (DeLorenzo et al., 1997; Freeman and Komaroff, 1997;
Schondorf et al., 1999), even more groups have not, including
the original research team reporting the finding (Razumovsky
et al., 2003), another group studying twins (Poole et al., 2000),
yet another studying a community sample of CFS patients
(Jones et al., 2005), and our own carefully controlled study
of unmedicated and uninstrumented patients (LaManca et al.,
1999).
Subsequently attention has turned away from delayed
hypotension to orthostatic tachycardia—defined as an increase
in heart rate from those in the supine position of ≥30 beats
per minute or rates of ≥130 beats per minute while standing.
Later studies suggested an important age factor in determining
the physiological form of OI. Almost every adolescent with CFS
had orthostatic tachycardia (Stewart et al., 1999), but this was not
the case with adults (Natelson et al., 2007) where rates appear
to be lower ranging from 10% (Naschitz et al., 2006) to 27%
(Hoad et al., 2008) with the higher rate found in UK patients
who reported having the diagnosis of CFS rather than being
directly diagnosed. In our own study of adult patients (Natelson
et al., 2007), orthostatic tachycardia was not common, occurring
in only 11% of patients, not significantly different from rates in
healthy controls.
While orthostatic tachycardia is not common in adults, ortho-
static hyperventilation—end tidal CO2 values lowered to below
30mmHg during orthostatic challenge—seems to be substan-
tially more common in that we found it occurred in 21% of adult
CFS patients compared to 3% in healthy controls (Natelson et al.,
2007). When we broke out the data by gender, we found ortho-
static hyperventilation to occur in 35% of the female patients—a
very substantial proportion (Natelson et al., 2007). The patients
with orthostatic hyperventilation showed a progressive fall in
end tidal CO2 during orthostatic challenge—a trend also seen,
albeit much milder, in CFS patients without OI or in healthy
controls. In a parallel study, a group of Israeli investigators
(Naschitz et al., 2006) also monitored end tidal CO2 in CFS
patients and found a rate of 31% showing hypocapnia (gender
not specified).
The common explanation for hyperventilation is anxiety. We
specifically asked volunteers in our study to rate their anxiety
on a visual analog scale (Natelson et al., 2007). While patients
both with and without OI had higher anxiety levels while
supine than controls that difference did not increase in the
OI group during orthostatic challenge. In fact, there were no
differences in groups apart from the initial shift noted at base-
line. Based on that result, we hypothesized that orthostatically-
induced hyperventilation represented a physiological response
to intra-thoracic hypovolemia related to blood pooling distally.
Novak et al. have come to a similar conclusion in their studies
of cerebral blood flow during orthostatic challenge in syncope
patients. They postulated that patients hyperventilate for several
reasons: first, to help pull blood into the chest by increasing
pre-load mechanically and next to combat decreases in blood
pressure by tachypnea-induced vasoconstriction (Novak et al.,
1998).
Finding orthostatic tachycardia or hyperventilation is a phys-
iological confirmation of the complaint of OI. While we do
not know whether physiological manifestation of OI correlates
with plasma isoprostanes or, inversely, with brain GSH (we are
currently doing studies to answer this question), another possi-
bility exists. Using two methods for determining absolute cerebral
blood flow, we have demonstrated reductions in CFS patients as
a group in the resting state (Yoshiuchi et al., 2006; Biswal et al.,
2011). We reported average blood flow and thus some patients
had blood flow in the normal range while others had flow that
was quite reduced relative to controls. We hypothesize that the
OI group may be the ones with the reduced brain blood flow at
rest and that this group of patients may show further decreases in
brain blood flow during orthostatic challenge. Only one study in
CFS patients exists to date on the effects of orthostatic challenge
on some measure of brain blood flow—i.e., middle cerebral arte-
rial blood velocity assessed by transcranial Doppler (Razumovsky
et al., 2003). Using this technique, no significant difference was
found in resting middle cerebral artery blood velocity between
patients and controls in the supine posture, and no difference was
found during orthostatic stress. However, only 10% of patients
in this study had OI, and this rate was the same as that in
controls. Not finding differences in either supine or challenged
postures may have two explanations: first, cerebral blood veloc-
ity may not reflect the same measure as absolute cerebral blood
flow and second, it may be important to have a larger group
of patients with OI and then to compare blood flow in that
group to those without OI. If that experiment were done, we
might expect that the patients with OI but not those without OI
will have dramatic decreases in cerebral blood flow with com-
mensurate increases in resistance due to orthostatically-induced
hyperventilation.
If this is the case, then we would expect that it is the patients
with OI who are at increased risk of developing the increased T2-
signal lesions we have reported to occur via a process leading to
sporadic cerebral hypoxia. As a corollary, we would expect that it
is these patients who have the most difficulty with cognitive pro-
cessing. Unfortunately, we had not been assessing CFS patients
for OI at the time of these earlier studies—a deficiency we are
now remedying in current work. We expect that OI will be more
common in patients with no history of psychiatric diagnosis than
in those with such diagnoses.
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In conclusion, we have been able to reduce substantially
patient pool heterogeneity by identifying phenotypicmarkers that
allow the researcher to stratify patients into subgroups. To date,
we have shown that stratifying based on the presence or absence
of comorbid psychiatric diagnosis leads to a group with evidence
of neurological dysfunction across a number of spheres. We have
also found that stratifying based on the presence or absence of
comorbid fibromyalgia leads to information that would not have
been found on analyzing the entire, unstratified patient group.
Objective evidence of OI may be another important variable for
stratification and may produce some of the symptoms of CFS
via intermittent cerebral hypoxia. We hope that this review will
encourage other researchers to collect data on discrete pheno-
types in CFS to allow this work to continue more broadly. Finding
subgroups of CFS suggests different underlying pathophysiologi-
cal processes responsible for the symptoms seen. Understanding
those processes is the first step toward developing discrete treat-
ments for each.
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